<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367341</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00026176</org_study_id>
    <nct_id>NCT00367341</nct_id>
  </id_info>
  <brief_title>Imaging Predictors of Treatment Response in Depression</brief_title>
  <official_title>Imaging Predictors of Treatment Response in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While there are many effective options for treating a major depressive episode, there are no&#xD;
      clinical markers that predict the likelihood of remission with an initial trial of either an&#xD;
      antidepressant medication or psychotherapy. More critically, there are also no reliable&#xD;
      predictors that might anticipate failure to such standard treatments either alone or in&#xD;
      combination. This project will characterize imaging-based brain subtypes that distinguish&#xD;
      groups of depressed patients who later remit or not to SSRI pharmacotherapy or cognitive&#xD;
      behavior therapy (CBT), respectively. To define these subtypes, a prospectively-treated&#xD;
      cohort of 100 patients will be randomized to receive either escitalopram (s-CIT) or CBT for&#xD;
      the first 12 weeks, with non-remitters to either first treatment crossed over to receive an&#xD;
      additional 12 weeks of treatment with combined treatment. Non-remitters to both treatments&#xD;
      will thus define a relatively treatment resistant third subgroup. Resting-state&#xD;
      18F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) scans will be acquired prior&#xD;
      to initiating antidepressant therapy, with pre-treatment scan patterns associated with three&#xD;
      possible outcomes (CBT remission, s-CIT remission, and non-remission to both) assessed using&#xD;
      multivariate analytic methods. A second PET scan, acquired early in the treatment course,&#xD;
      will be used to assess the likelihood of response to the specific treatment first assigned.&#xD;
      The proposed studies are a first step towards defining brain-based biomarkers predictive of&#xD;
      differential treatment outcome in major depression; most critically, patterns distinguishing&#xD;
      patients at risk for treatment resistance. Identification of such biomarkers has additional&#xD;
      implications for future testing of novel therapies in patients with distinct brain&#xD;
      signatures, including development of evidence-based treatment algorithms for individual&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPECIFIC AIMS Aim 1. To define baseline regional glucose metabolic patterns (measured using&#xD;
      FDG PET) associated with differential clinical remission to each of two well-established,&#xD;
      randomly delivered first-line antidepressant treatments-the SSRI escitalopram (s-CIT) or&#xD;
      cognitive behavioral therapy (CBT) with cross-over treatment for non-remitters (sequential&#xD;
      course of treatment model).&#xD;
&#xD;
      Aim 2. To define metabolic change patterns, occurring early in the course of both s-CIT and&#xD;
      CBT, associated with successful and unsuccessful clinical remission to each intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks</measure>
    <time_frame>Measured at week 12</time_frame>
    <description># of study participants with Hamilton Depression-17-item score less than or equal to 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks</measure>
    <time_frame>Measured at week 12.</time_frame>
    <description>Number of participants with a 50% change from Baseline on the Hamilton Depression Rating Scale-17-item score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>Participants will receive treatment with escitalopram for 12 weeks.</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>CBT will include 16 1 hour sessions provided over 12 weeks.</description>
    <arm_group_label>Cognitive Behavioral Therapy</arm_group_label>
    <other_name>Talk Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between the ages of 18 and 60. (no subjects with first episode&#xD;
             over age 50. This is an attempt to exclude patients with 'vascular depression' who&#xD;
             have a potentially different pathophysiology and treatment response compared to&#xD;
             idiopathic MDD.&#xD;
&#xD;
          -  DSM-IV criteria for unipolar Major Depressive Disorder.&#xD;
&#xD;
          -  HAM-D (24 item) score &gt;/= 18 at Screening, &gt;/= 15 at Baseline.&#xD;
&#xD;
          -  Co-morbid conditions (other than those listed under exclusion criteria below) will be&#xD;
             accepted as long as MDD is the primary diagnosis (based on predominance and sequential&#xD;
             development of symptoms).&#xD;
&#xD;
          -  Acceptable method of birth control (oral contraceptives, Depo-Provera, Norplant,&#xD;
             condoms with spermicide. A vasectomy is acceptable in the framework of a stable&#xD;
             monogamous relationship. Sexually inactive women must agree to contraception if they&#xD;
             become sexually active during the study.&#xD;
&#xD;
          -  Educational level, degree of understanding and reliability so that participation is&#xD;
             feasible.&#xD;
&#xD;
          -  Informed consent to participate and comply in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known neurological disorders or documented head injury.&#xD;
&#xD;
          -  Serious and unstable medical illnesses including diabetes, cardiovascular disease and&#xD;
             cancer.&#xD;
&#xD;
          -  Medical conditions with known mood changes (endocrine, autoimmune disorders)&#xD;
&#xD;
          -  Co-morbid DSM-IV Axis I Diagnoses&#xD;
&#xD;
               1. Lifetime history of Bipolar Disorder, Schizophrenia, and other Psychotic&#xD;
                  Disorders, or Obsessive Compulsive Disorder&#xD;
&#xD;
               2. Alcohol abuse or dependence within the past six months, psychoactive substance&#xD;
                  abuse or dependence within the past six months.&#xD;
&#xD;
               3. Clinical evidence of a severe Personality Disorder that would impede&#xD;
                  participation or completion of a controlled trial.&#xD;
&#xD;
          -  ECT within the past 6 months.&#xD;
&#xD;
          -  Previous failure to achieve a much improved status on CGI-Improvement (the equivalent&#xD;
             of &gt;50% symptom reduction) with a course of CBT (defined as a minimum of 8 sessions&#xD;
             during 8 weeks of a specified manual-driven therapy by a CBT trained therapist) or&#xD;
             escitalopram (defined as a minimum of 6 weeks with the dose of 10 mgs achieved for at&#xD;
             least 2 weeks)&#xD;
&#xD;
          -  Use of concomitant medications with the exception of:&#xD;
&#xD;
               1. Maintenance/prophylactic meds for stable medical conditions&#xD;
&#xD;
               2. Ambien 5-10 mgs may be prescribed for occasional use (up to a single dose a week&#xD;
                  for insomnia, as long as it is not the night before a clinic visit, PET/fMRI&#xD;
                  study or ratings.&#xD;
&#xD;
               3. Antidepressants will be discontinued for 7 days prior to the screening visit,&#xD;
                  which will be a minimum of a week before the baseline scan (5 weeks for&#xD;
                  fluoxetine, protryptyline).&#xD;
&#xD;
          -  Current treatment with weekly individual or group psychotherapy targeted at the&#xD;
             depressive symptoms, including psychodynamic, interpersonal or cognitive-behavioral.&#xD;
&#xD;
          -  Currently responding to medication treatment, without clinical reasons to change (e.g.&#xD;
             side effects). Will not enroll a subject who wishes to discontinue an effective&#xD;
             treatment for the sake of participation in the research.&#xD;
&#xD;
          -  Woman who are pregnant, breast feeding or intending to become pregnant during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Contraindications for MRI: pacemaker, aneurysm clips, neurostimulators, cochlear&#xD;
             implants, metal in eyes, steel worker, or other implants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Mayberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.emoryclinicaltrials.com</url>
    <description>website with study information</description>
  </link>
  <results_reference>
    <citation>McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013 Aug;70(8):821-9. doi: 10.1001/jamapsychiatry.2013.143.</citation>
    <PMID>23760393</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>August 18, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <results_first_submitted>November 21, 2013</results_first_submitted>
  <results_first_submitted_qc>November 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2014</results_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Helen Mayberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression, Treatment, Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram</title>
          <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram</title>
          <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="6.8"/>
                    <measurement group_id="B2" value="42.2" spread="9.5"/>
                    <measurement group_id="B3" value="41.68" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks</title>
        <description># of study participants with Hamilton Depression-17-item score less than or equal to 7.</description>
        <time_frame>Measured at week 12</time_frame>
        <population>completed study participants in 12-week-trial</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks</title>
          <description># of study participants with Hamilton Depression-17-item score less than or equal to 7.</description>
          <population>completed study participants in 12-week-trial</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks</title>
        <description>Number of participants with a 50% change from Baseline on the Hamilton Depression Rating Scale-17-item score</description>
        <time_frame>Measured at week 12.</time_frame>
        <population>completers</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Behavioral Therapy</title>
            <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks</title>
          <description>Number of participants with a 50% change from Baseline on the Hamilton Depression Rating Scale-17-item score</description>
          <population>completers</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram</title>
          <description>escitalopram : Participants will receive treatment with escitalopram for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Cognitive Behavioral Therapy</title>
          <description>Cognitive Behavioral Therapy (CBT) : CBT will include 16 1 hour sessions provided over 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>indigestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>stomach cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>decreased libido</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Helen Mayberg, MD</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-727-6740</phone>
      <email>hmayber@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

